Pfizer was founded in 1849 in Brooklyn, New York, by cousins Charles Pfizer and Charles Erhart. Initially, the company produced fine chemicals, and its first product was an antiparasitic called santonin, which was used to treat intestinal worms. The business grew steadily, and by the early 20th century, Pfizer had become a major manufacturer of citric acid and other industrial chemicals.
The company’s transformation into a pharmaceutical powerhouse began during World War II, when Pfizer was one of the first companies to mass-produce penicillin. This achievement not only saved countless lives but also established Pfizer as a leader in antibiotic production. In the years that followed, Pfizer expanded its research capabilities and launched a series of blockbuster drugs, including Terramycin (oxytetracycline) in 1950, which became the first antibiotic discovered through a systematic soil-screening program.
Throughout the latter half of the 20th century, Pfizer continued to grow through a combination of internal research and strategic acquisitions. Notable acquisitions include Warner-Lambert (2000), Pharmacia (2003), and Wyeth (2009). These moves brought Pfizer a vast array of drugs and vaccines, and helped solidify its position as one of the largest pharmaceutical companies in the world.
Pfizer’s portfolio spans several major therapeutic areas, including:
- **Vaccines** – Perhaps the most famous recent product is the Pfizer‑BioNTech COVID‑19 vaccine (Comirnaty). Developed in partnership with the German company BioNTech, this mRNA vaccine was the first to receive emergency use authorization in many countries and has been administered to billions of people worldwide. Pfizer also produces Prevnar 13 and Prevnar 20, vaccines that protect against pneumococcal disease, and is a leader in the vaccine space.
- **Oncology** – Pfizer has a strong oncology pipeline, including drugs for breast cancer (Ibrance), prostate cancer (Xtandi), and a range of targeted therapies. The company’s acquisition of Array BioPharma in 2019 added important drugs for colorectal and other cancers.
- **Inflammation and Immunology** – The company developed Xeljanz, used for rheumatoid arthritis and other inflammatory conditions, and has a growing portfolio in autoimmune diseases.
- **Primary Care** – Pfizer’s primary care products include cholesterol-lowering medications (Lipitor, though now generic), blood pressure drugs, and over-the-counter products like Advil (ibuprofen) and Centrum (multivitamins), which are part of the consumer health division that was later spun off.
- **Hospital** – Pfizer provides injectable drugs, anti-infectives, and sterile products used in hospitals for critical care.
- **Rare Disease** – Through its acquisition of Biohaven and other deals, Pfizer has expanded into rare disease treatments, including therapies for neuromuscular disorders.
Pfizer invests heavily in research and development, spending over $10 billion annually. The company’s R&D strategy focuses on both internal innovation and external partnerships. In recent years, Pfizer has shifted toward a more agile, “small molecule” and “biologics” approach, with a strong emphasis on mRNA technology following the success of the COVID-19 vaccine.
The company’s pipeline includes candidates for respiratory syncytial virus (RSV), shingles, and next-generation COVID-19 vaccines. Pfizer is also exploring gene therapies and cell therapies for rare genetic disorders. The company’s ability to rapidly develop and scale up the COVID-19 vaccine demonstrated its operational efficiency and scientific expertise.
Pfizer has made commitments to improving global health access. During the pandemic, it pledged to provide its COVID-19 vaccine at a not-for-profit price to low- and middle-income countries. The company also participates in global health initiatives such as the Global Health Innovation Fund and partnerships to combat infectious diseases like pneumonia and meningitis.
In addition, Pfizer has set sustainability goals, including reducing its environmental footprint and increasing diversity in clinical trials. The company’s “Health for All” strategy aims to ensure that its medicines reach those who need them most, regardless of geography or income level.
As of 2025, Pfizer continues to evolve. The company is investing heavily in its mRNA platform, exploring vaccines for influenza, shingles, and other conditions. It has also expanded into the weight‑loss drug space, a highly competitive market, with candidates targeting obesity and diabetes.
Pfizer’s recent acquisition of Seagen (a leading cancer drug company) for $43 billion, finalized in 2024, was a major move to strengthen its oncology pipeline. The company also partially spun off its consumer health division into a joint venture with GSK, creating Haleon, which now manages brands like Advil and Centrum.
Financially, Pfizer remains a robust company, though it faces challenges from patent expirations and the post-pandemic decline in COVID-19 vaccine and treatment sales. The company is actively managing its portfolio by cutting costs, focusing on high-growth areas, and pursuing strategic deals.
**Is Pfizer a US company?**
Yes, Pfizer is headquartered in New York City and is a US-based multinational pharmaceutical corporation.
**What is Pfizer’s most famous product?**
The COVID-19 vaccine (Comirnaty) is its most widely recognized product, but many of its drugs, such as Lipitor (atorvastatin) and Viagra (sildenafil), have also been blockbusters.
**Does Pfizer only make vaccines?**
No, Pfizer develops and markets a wide range of medicines, including treatments for cancer, inflammation, rare diseases, and hospital care. Vaccines are just one part of its business.
**How does Pfizer develop new drugs?**
Pfizer uses a combination of internal research, partnerships with biotech companies, and acquisitions. It employs thousands of scientists and invests heavily in R&D.
**What is the future of Pfizer?**
Pfizer is focusing on mRNA technology, oncology, and rare diseases. It aims to offset revenue losses from patent expirations by launching new products and expanding into high-demand areas like obesity.
Pfizer is far more than just the company behind the COVID-19 vaccine. With a history that stretches back to the mid-19th century, it has consistently been at the forefront of pharmaceutical innovation. From antibiotics to vaccines, cancer therapies to gene therapies, Pfizer’s impact on global health is immense. The company continues to adapt to changing market conditions while maintaining a strong commitment to research and development. Whether you are a healthcare professional, an investor, or simply someone curious about the medicines that shape our world, understanding Pfizer gives you a window into the business of saving lives.